Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
RADREMI trial: what clinicians have said so far
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
- NCT04047602 ↗
- Terminated
- Indiana University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RADREMI (brain metastases on immunotherapy; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RADREMI so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X, typically up to 35 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
- Phase
- Phase not applicable
- Status
- Terminated
- Conditions
- Brain Tumor; Brain Metastases; Brain Cancer
- Interventions
- Reduced Dose SRS
- Arms
- Reduced Dose Stereotactic Radiosurgery · Experimental
- Enrollment
- 18
- Primary outcomes
- Symptomatic Radiation Necrosis Proportion
- Sponsor
- Indiana University
- Start
- Dec 12, 2019
- Primary completion
- Jul 25, 2023
- Results posted
- Yes
- Registry record
- NCT04047602 · updated Feb 13, 2025
Publications
linked from the registry- McClelland S 3rd, Lautenschlaeger T, Zang Y, Hanna NH, Shiue K, Kamer AP, Agrawal N, Ellsworth SG, Rhome RM, Watson GA. Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol. Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):500-506. doi: 10.1016/j.rpor.2020.04.007. Epub 2020 Apr 23. PubMed 32477016